부산대학교 도서관

Background In patients with resectable stage III non-small cell lung cancer (NSCLC), induction chemoimmunotherapy followed by surgical resection has shown unprecedented rates of pathological response and event-free survival. However, a triple-induction including radiochemotherapy and immunotherapy followed by surgical resection has not been routinely established in clinical practice. Case presentation We report the case of a 47-year-old patient with stage IIIA NSCLC who was treated in a combined concept including induction concurrent radiochemotherapy, followed by 4 cycles of pembrolizumab and subsequent intrapericardial left-sided pneumonectomy. Histological analysis revealed a pathological complete response. Conclusions The case demonstrates that the combination of neoadjuvant chemo-, radio- and immunotherapy in advanced NSCLC may lead to a relevant down-staging and may enable a R0-resection of a borderline resectable tumor. However, the combination of four different treatment modalities requires resilience and a good performance status. A triple induction treatment may be a promising option for selected patients with locally advanced NSCLC and good performance status. Keywords: Advanced lung cancer, Pneumonectomy, Multimodality treatment, Pathological complete response, Case report
Author(s): Raphael S. Werner[sup.1,2], Olivia Lauk[sup.1,2], Georg Tscherry[sup.3], Alessandra Curioni-Fontecedro[sup.3,4,5], Sylvia Höller[sup.6,7] and Isabelle Opitz[sup.1,2] Background Among patients with non-small cell lung cancer (NSCLC), approximately one third presents with stage [...]